Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan‐O trial testing a titratable fixed‐ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents

To determine whether baseline characteristics had an impact on clinical outcomes in the LixiLan‐O trial (N = 1170), we compared the efficacy and safety of iGlarLixi, a titratable fixed‐ratio combination of insulin glargine 100 U (iGlar) and lixisenatide (Lixi) with iGlar or Lixi alone in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Melanie J., Leiter, Lawrence A., Guerci, Bruno, Grunberger, George, Ampudia‐Blasco, F. Javier, Yu, Christine, Stager, William, Niemoeller, Elisabeth, Souhami, Elisabeth, Rosenstock, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697595/
https://www.ncbi.nlm.nih.gov/pubmed/28432746
http://dx.doi.org/10.1111/dom.12980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697595/
https://www.ncbi.nlm.nih.gov/pubmed/28432746
http://dx.doi.org/10.1111/dom.12980

Ejemplares similares